Menu Search
Equities

DMK Pharmaceuticals Corp

CY3:MUN

DMK Pharmaceuticals Corp

Actions
  • Price (EUR)0.264
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-90.16%
  • Beta--
Data delayed at least 15 minutes, as of Feb 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.

  • Revenue in USD (TTM)3.62m
  • Net income in USD-21.16m
  • Incorporated2004
  • Employees11.00
  • Location
    DMK Pharmaceuticals Corp11682 El Camino Real, Suite 300SAN DIEGO 92130United StatesUSA
  • Phone+1 (858) 997-2400
  • Fax+1 (302) 636-5454
  • Websitehttps://www.dmkpharmaceuticals.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.